BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) stock suffered a major decline of -10.1% on 12/6/23. The shares closed at $5.51. Moreover, exceptionally high trading volume at 489% of normal accompanied the decline. The stock has been weak relative to the market over the last nine months but has risen 2.2% during the last week.
Current PriceTarget Research Rating
BCRX is expected to be a major Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
BioCryst Pharmaceuticals is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment